Start with the medical reason for compounding
A “best compounding pharmacy for tirzepatide” ranking cannot establish that a compounded prescription is appropriate for you. FDA recommends compounded drugs only when medical needs cannot be met by an approved drug. Compare the proposed preparation with available approved treatment before choosing a pharmacy.
Semaglutide and tirzepatide are not currently on FDA’s drug shortage list or the 503B bulks list according to its April 2026 clarification. Earlier shortage-driven access should not be presented as a permanent approval or a current universal exemption.
Sources: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA · FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA
Verify the actual dispensing pharmacy
A telehealth platform and a dispensing pharmacy are different entities. Obtain the pharmacy’s legal name, address and license information, and verify that it can dispense in your state. Compare those details with the label on the delivered medicine. FDA describes cases in which fraudulent labels named nonexistent pharmacies or pharmacies that did not make the product.
A reference to “FDA registered” or “503A” does not mean an individual compounded drug is FDA-approved. Registration, licensing, inspections and the conditions of a particular prescription are separate questions. Ask the prescriber and pharmacy to explain the applicable pathway rather than infer it from a badge.
Sources: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA · FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA
Ask about ingredients, concentration and instructions
The approved tirzepatide products are injections. A compounded tablet or dissolvable preparation should not be described as approved Zepbound or Mounjaro. Ask for evidence about the actual route and formulation instead of relying on injectable-trial results.
Confirm the prescribed milligram dose, concentration, volume and exact syringe instructions for the supplied vial. Syringe units are not milligrams. If a concentration changes, instructions from an earlier supply may no longer apply. Have the pharmacist resolve any mismatch before use.
Sources: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA · Zepbound prescribing information · Mounjaro prescribing information
Quality questions continue after delivery
FDA advises against using injectable GLP-1 medicine that arrives warm or insufficiently refrigerated. Contact the dispensing pharmacy about a temperature concern instead of assuming an ice pack or an intact label proves usability. Follow product-specific storage and handling instructions.
Its current guidance on compounded multidose vials recommends disposal within 28 days after first use even if compounder instructions allow longer. Ask how the planned supply fits that guidance. Use a new sterile needle and syringe for every dose and obtain instructions for disposal of sharps.
No public ranking establishes sterility, potency or stability of your individual supply. We do not score medication quality or recommend a pharmacy based on fictional experience. Ask about the product, pharmacy documentation, complaint process and clinical support for the prescription actually proposed.
Sources: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA